Vienna June 30th, 2026 - YGION today announces it has received regulatory approval for its Clinical Trial Application (CTA) for YG-01. YG-01 is YGION’s personalized neoantigen immunotherapy and is initially being developed for newly diagnosed glioblastoma in the adjuvant setting, with the goal of eliminating residual disease following standard-of-care treatment. YGION’s CTA approval enables the company to initiate its first-in-human Phase 1 study in the EU. The planned dose-escalation study will evaluate YG-01 in glioblastoma patients, representing an important step forward in the development of the program. YG-01 combines YGNITE™, YGION’s AI-driven neoantigen discovery engine, with its proprietary CARGONAUT™ delivery platform to deliver neoantigens to antigen-presenting cells and activate a tumor-specific immune response. The company’s approach is designed to ...

CSO Dr Anna-Dorothea Gorki and Scientist Dr Vanessa Mühlgrabner will be attending the 2026 Annual Congress of the European Association for Cancer Research on June 8th-11th in Budapest. The team will be joining an international audience to hear about the latest updates in basic, preclinical and translational cancer research across a wide breadth of topics.

CBO, Dr Sophie Zettl will be attending key partnering and investment conferences this Spring to discuss collaboration and investment opportunities at YGION Biomedical. On March 23-26th 2026, YGION will be attending BioEurope Spring and LSX in Lisbon, Portugal, and BioEquity on May 4-6th 2026 in Prague, Czech Republic These premier European partnering conferences bring together the global life sciences community to accelerate collaboration and dealmaking.

YGION Biomedical’s CSO, Dr Anna-Dorothea Gorki is attending the 8th International Neoantigen Summit on June 24-26, in Amsterdam, Netherlands. This conference brings together the global neoantigen community to address key challenges in the discovery, translation and clinical development of safe and cost-effective neoantigen therapies and vaccines to attract investors and ultimately improve the health of patients. www.neoantigen-summit.com

The YGION Biomedical team will be attending a number of international conferences this Autumn. To explore partnerships in Asia and beyond, the team will be joining the Austrian delegation of the EU-Japan Biotech & Pharma Partnering Conference on 7-9th October 2024 in Osaka, Japan, followed by BioJapan 2024 in Yokohama, Japan. On October 10-11th 2024, the team will join key players from the Austrian and international biotech industry at the 2nd Biotech Summit Austria in Innsbruck, Austria. On November 4-6th 2024, the team will attend Europe's premier partnering event, BioEurope 2024 in Stockholm, Sweden. These international conferences connect delegates spanning the global life science ecosystem to propel dealmaking and innovation. BioJapan 2024 Biotech Austria Summit BioEurope 2024 ...

YGION Biomedical GmbH, a company dedicated to developing individualized neoantigen-based cancer immunotherapies, today announces further fundraising news with the award of a significant Life Sciences grant from the Austrian Research Promotion Agency (Forschungsförderungsgesellschaft; FFG). This non-dilutive funding will be used over the next 12 months to further development YGION’s unique YGNITE™ technology platform and support preclinical development of YGION’s lead program, YG1. YGION is committed to developing individualized “plug-and-play” cancer vaccines using a proprietary suite of technologies to identify, produce and target the delivery of relevant peptide neoantigens resulting in safe, exceptionally potent, and precise targeted activation of the patient’s immune system. “With this support from the FFG, we will take an important step forward ...

YGION Biomedical GmbH, a company dedicated to developing individualized neoantigen-based cancer vaccines, today announced the completion of a Series A financing round of €15 million from an Austrian private trust. The proceeds will be used to further develop YGION’s unique YGNITE™ technology platform and advance the lead program YG-01 into preclinical and clinical development. Founded in 2022, YGION’s high-profile team of experienced biotech veterans and entrepreneurs are focused on developing individualized “plug-and-play” cancer vaccines through a proprietary suite of technologies to identify, produce and target the delivery of relevant peptide neoepitopes resulting in safe, exceptionally potent, and precise targeted activation of the patient’s immune system. “We are on the cusp of a breakthrough in individualized cancer treatments” said ...

YGION Biomedical’s team is attending the 7th International Neoantigen Summit from April 29 – May 1, in Amsterdam, Netherlands. This meeting unites the international neoantigen community to overcome neoantigen identification, prediction, and translational challenges that are holding back the full potential of this class of therapies. www.neoantigen-summit.com